Melanoma (primary nd
Contact us: [email protected]
Melanoma Tissue Array - 12 cases of normal epithelium, nevus, and carcinoma of the skin, and 36 cases of primary (26 cases) and metastatic (10 cases) melanomas in duplicates. |
Z7020108 |
Biochain |
5 slides |
EUR 1657.2 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Melanoma Tissue Slide (Skin- Melanoma) |
12-801-10um |
ProSci |
10 um |
EUR 241.8 |
Melanoma Tissue Slide (Skin- Melanoma) |
12-801-4um |
ProSci |
4 um |
EUR 216.6 |
Malignant melanoma |
ME1004h |
TissueArray |
each |
EUR 306 |
Description: Malignant melanoma, metastatic malignant melanoma and nevus tissue array, including pathology grade, TNM and clinical stage, 100 cases/100 cores, replacing ME1004g |
Malignant melanoma |
ME1006 |
TissueArray |
each |
EUR 378 |
Description: Malignant melanoma, metastatic malignant melanoma and nevus tissue array, including TNM and clinical stage (AJCC 8th edition), 100 cases/ 100 cores (core size 1.0mm),replacing ME1004h |
Human Melanoma CAFs |
CAF09 |
Neuromics |
1,000,000 cells |
EUR 1749.6 |
Melanoma tissue array |
ME483 |
TissueArray |
each |
EUR 270 |
Description: Melanoma tissue array, including TNM and clinical stage, 48 cases/48 cores, replaced by ME483a |
Melanoma (gp100) Protein |
20-abx263540 |
Abbexa |
-
EUR 994.80
-
EUR 493.20
-
EUR 644.40
|
|
|
Melanoma Antibody / PNL2 |
V3071-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF. |
Melanoma Antibody / PNL2 |
V3071-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF. |
Melanoma Antibody / PNL2 |
V3071IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 349.3 |
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF. |
Melanoma Antibody / PNL2 |
V3071SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF. |
Melanoma, 48 cases (1.5mm) |
MEL961 |
Pantomics |
1 |
EUR 372 |
Description: Melanoma tissue array containing 12 cases of normal epithelium, nevus and carcinoma of the skin, and 36 cases of primary (26 cases) and metastatic (10 cases) melanomas in duplicates. |
GFP-HUVEC (Primary) |
P0027003 |
Addexbio |
One Frozen vial |
EUR 1066 |
TnI (Primary) Antibody |
abx018056-100ug |
Abbexa |
100 ug |
EUR 410.4 |
|
Primary Human Neurons |
HNC001 |
Neuromics |
300,000 Cyroperserved Cells |
EUR 1467.6 |
Melanoma (skin cancer) Exosome |
P141-MN |
101Bio |
- |
Ask for price |
Melanoma Marker(PNL2) Antibody |
BNC800894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF680 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC800894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF680 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC810894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF680R conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC810894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF680R conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC940894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF594 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC940894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF594 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC700894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF770 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC700894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF770 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC880894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF488A conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC880894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF488A conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC050894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF405M conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC050894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF405M conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC040894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF405S conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC040894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF405S conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC400894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF640R conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC400894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF640R conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCB0894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), Biotin conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCB0894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), Biotin conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCAP0894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCAP0894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCA0894-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Melanoma Marker(PNL2), APC conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCR0894-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Melanoma Marker(PNL2), RPE conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCP0894-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Melanoma Marker(PNL2), PerCP conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNUM0894-50 |
Biotium |
50uL |
EUR 474 |
Description: Primary antibody against Melanoma Marker(PNL2), 1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCH0894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCH0894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNUB0894-100 |
Biotium |
100uL |
EUR 250.8 |
Description: Primary antibody against Melanoma Marker(PNL2), Concentration: 0.2mg/mL |
Melanoma Marker(PNL2) Antibody |
BNUB0894-500 |
Biotium |
500uL |
EUR 549.6 |
Description: Primary antibody against Melanoma Marker(PNL2), Concentration: 0.2mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC610894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF660R conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC610894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF660R conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC550894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF555 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC550894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF555 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC430894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF543 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC430894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF543 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC680894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF568 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC680894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF568 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC470894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF647 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC470894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF647 conjugate, Concentration: 0.1mg/mL |
PMEL17 / Melanoma gp100 Antibody |
V3472-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa. By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This MAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. This MAb stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. This MAb also stains Angiomyolipoma (PEComa). |
PMEL17 / Melanoma gp100 Antibody |
V3472-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa. By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This MAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. This MAb stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. This MAb also stains Angiomyolipoma (PEComa). |
PMEL17 / Melanoma gp100 Antibody |
V3472IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 349.3 |
Description: The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa. By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This MAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. This MAb stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. This MAb also stains Angiomyolipoma (PEComa). |
PMEL17 / Melanoma gp100 Antibody |
V3472SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa. By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This MAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. This MAb stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. This MAb also stains Angiomyolipoma (PEComa). |
PMEL17 / Melanoma gp100 Antibody |
V9078-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H & E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. It stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa fragments. |
PMEL17 / Melanoma gp100 Antibody |
V9078-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H & E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. It stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa fragments. |
PMEL17 / Melanoma gp100 Antibody |
V9078IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 349.3 |
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H & E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. It stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa fragments. |
PMEL17 / Melanoma gp100 Antibody |
V9078SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H & E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. It stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa fragments. |
PMEL17 / Melanoma gp100 Antibody |
V9079-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.This Mab labels formalin-fixed, paraffin-embedded melanomas and other tumors showing melanocytic differentiation. |
PMEL17 / Melanoma gp100 Antibody |
V9079-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.This Mab labels formalin-fixed, paraffin-embedded melanomas and other tumors showing melanocytic differentiation. |
PMEL17 / Melanoma gp100 Antibody |
V9079SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.This Mab labels formalin-fixed, paraffin-embedded melanomas and other tumors showing melanocytic differentiation. |
PMEL17 / Melanoma gp100 Antibody |
V3916-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: PMEL17/Melanoma gp100/SILV plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity. [UniProt] |
Melanoma (primary nd